Cleveland Biolabs Inc. and Incuron Announce CBL0102 Orphan Drug Status for Hepatocellular Carcinoma

Published: Oct 02, 2012

BUFFALO, N.Y., Oct. 2, 2012 (GLOBE NEWSWIRE) -- Cleveland BioLabs, Inc. (Nasdaq:CBLI) and Incuron, LLC, a joint venture between the Company and Bioprocess Capital Ventures, today announced that curaxin CBL0102 (quinacrine) has been granted Orphan Drug status by the U.S. Food and Drug Administration (FDA) for treatment of hepatocellular carcinoma.

Back to news